Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 5 of 34« First...34567...102030...Last »

UK to ‘fast track’ most cost-effective new drugs

Britain’s healthcare cost agency NICE plans to fast-track its recommendations for the most cost-effective new drugs.

Read More »

Most U.S. dermatologists receive industry money

Nearly three-quarters of U.S. dermatologists received payments worth a collective $34 million from drug companies in 2014, according to a new analysis of a public database.

Read More »

Merrimack CEO Resigns, Company Slashes Jobs

Robert Mulroy, CEO of Merrimack Pharmaceuticals, has resigned his position as part of a corporate restructuring move that will result in a 22 percent workforce reduction.

Read More »

Regeneron’s Eylea combo therapy fails study

Regeneron Pharmaceuticals’ combo therapy containing its flagship eye drug, Eylea, was inferior to Eylea alone in a mid-stage trial involving patients with wet AMD.

Read More »

Amgen’s Kyprolis falls short in study

Amgen’s multiple myeloma drug did not fare better than Takeda’s older therapy Velcade in a study involving patients who had not yet been treated for the disease.

Read More »

FDA approves J&J’s Stelara for Crohn’s disease

Johnson & Johnson said the U.S. Food and Drug Administration approved the company’s blockbuster psoriasis drug Stelara for adults with Crohn’s disease.

Read More »

Novartis’ Zykadia gets positive results

Novartis’ Zykadia drug performed well against a rare form of lung cancer, citing a study the Swiss company hopes will help it win expanded regulatory approval.

Read More »

U.S. approves Aralez pill for heart patients

The U.S. FDA approved a pill that combines aspirin and the acid-fighting drug omeprazole to guard against gastric ulcers in patients who require daily aspirin.

Read More »

Takeda: Bold, New Access To Medicines Strategy

Takeda announced the launch of an Access to Medicines (AtM) strategy aimed at increasing access to its innovative and potentially life-saving medicines.

Read More »

Lung cancer doctors eye Keytruda over Opdivo

Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say.

Read More »

Mylan offers discounts on EpiPen after criticism

Mylan NV said it would reduce the out-of-pocket cost of its severe allergy treatment EpiPen through a discount program after lawmakers criticized the drug’s high price.

Read More »

Can anything contain U.S. drug costs?

The U.S., which spends more on drugs than any other country, might contain costs by limiting market exclusivity for brand name medicines and changing coverage requirements for government health plans, some doctors argue.

Read More »

2016 Annual Report: Top 200 Medicines

AbbVie’s biologic therapy Humira for autoimmune diseases was the worldwide prescription-drug sales leader in 2015 for the fourth consecutive calendar term.

Read More »

Special Feature: First Year After Launch

The new generation of hep C drugs has completely changed the conversation about launches.

Read More »

U.S. court backs UCB drug patent, shares jump

A ruling by the Delaware District Court in the United States upheld the validity of UCB’s patent for the epilepsy drug Vimpat.

Read More »

UK cost approval for longer use of heart drug

Long term use of AstraZeneca’s blood thinner Brilinta has been recommended as a cost-effective option in the UK for treating patients after a heart attack.

Read More »

Bristol-Myers shares hit by decline of Yervoy

Bristol-Myers Squibb reported disappointing 2Q 2016 sales of its Yervoy melanoma treatment.

Read More »

J&J shares on track for record high

J&J raised its full-year 2016 sales and earnings forecasts and reported quarterly results that beat estimates, helped by strength in its Rx drugs business.

Read More »

U.S. health spending to rise 5.8% a year through 2025

Healthcare spending in the United States will likely grow by an average 5.8 percent per year over the next decade according to updated projections from the federal government.

Read More »

Future of Post-Patent Protection for Humira

Investors in AbbVie are getting a bit antsy as that company’s blockbuster rheumatoid arthritis drug Humira loses its patent protection later this year.

Read More »

Page 5 of 34« First...34567...102030...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!

Subscribe

Ad Right Bottom

Main Navigation